According to the research report titled ‘Hip Reconstruction Devices Market Insights, Competitive Landscape and Market Forecast-2026’, available with Market Study Report, global hip reconstruction devices market is slated to record a strong compound annual growth rate throughout 2018-2026.
 

Increasing cases of arthritis owing to sedentary lifestyle coupled with rising awareness of availability of cost-effective hip injury-related therapies are the primary factors driving global hip reconstruction devices market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3557570/
 

For the record, hip reconstruction operations are performed to repair the glenohumeral joint with a prosthetic implant comprising of metal parts and polyethylene.
 

Elaborating on the factors hindering the industry progression, postoperative problems associated with hip replacement procedures and high costs for best hip replacement equipment are negatively impacting the business dynamics.
 

Based on product range, global hip reconstruction devices market is segmented into primary hip reconstruction devices, hip resurfacing devices, and partial hip reconstruction devices among others. Speaking of the end user spectrum, the industry is divided into hospitals and orthopedic clinics including others.
 

Worldwide hip reconstruction devices industry, based on geographical analysis, is fragmented into Spain, France, Germany, the United Kingdom, Spain, Japan, and the United States. The study entails a detailed coverage of the current and predicted sizes of these markets to help stakeholders in making identifying major investment areas for the upcoming years.
 

Leading players in worldwide hip reconstruction devices industry sphere are Evolutis SAS, Exactech Inc., DJO Global Inc., Conmed Corporation., Smith & Nephew plc, Wright Medical Group N.V., Johnson & Johnson, Arthrex Inc., Zimmer Biomet Holdings Inc., and Integra Lifesciences Corp. The research literature studies each of these players with respect to their product portfolio, strategic undertakings, and financial status.